Again, I think I'll come back to the comments others have made. It's CETA and the TPP in combination.
We were very concerned about the patent extension, that the two years would mean that development and manufacturing in Canada would put you behind the curve, that you're not going to be able to develop it as early as possible. An important element for us in that patent extension is that there will be an export clause, meaning companies.... Even though you're not going to be able to sell it in Canada for two more years and drug costs will stay high in Canada, you would be able to manufacture it for export to countries where patents have expired.
That's an important element for us in CETA and in the TPP.